June 9, 2017

Phase 1 Trial Results Show JTX-2011 was Well-tolerated in Advanced Solid Tumors

News

Jounce Therapeutics’ JTX-2011 was well-tolerated by patients with advanced solid tumors in the Phase 1/2 ICONIC clinical trial (NCT02904226), alone or in combination with Opdivo (nivolumab), supporting advancement of the ... Read more

July 22, 2016July 22, 2016

Jounce Joins with Celgene for Immuno-Oncology Therapies

News

Jounce Therapeutics has entered into a major strategic collaboration with Celgene Corporation to develop and commercialize Jounce’s lead product candidate JTX-2011, and other immunotherapies targeting B-cells and T regulatory cells. JTX-2011, Jounce’s product ... Read more